BioNTech Expands Restructuring Plan to Include JPT Peptides, Targeting Over 1,860 Job Cuts Amid Strategic Shift to Oncology

▲9April 4-5   CBI Biopharmaceutical Innovation Expo Scan the QR code to register

Note:This article does not constitute any investment advice or recommendations; please refer to official/company announcements for accuracy.This article is intended solely for the introduction of medications related to medical health and does not constitute a recommendation for treatment plans (if involved), nor does it represent the platform's stance.Authorization is required for any article reprint.

YaoRongQuan DataMonitoring shows: In May 2026, German giant BioNTech SE plans to further streamline and integrate its production bases in regions with excess capacity. The drivers for this adjustment include multiple factors such as changes in market supply and demand, mergers and acquisitions integration, partners’ production support capabilities, and the expiration of relevant cooperation contracts.

At that time, BioNTech planned to shut down.4 sitesProduction facilities, located in Idar-Oberstein, Marburg, Tübingen (the former CureVac headquarters site), and Singapore, will be affected by this optimization, impacting a total of up to approximately 1,860 positions. The three German sites in Idar-Oberstein, Marburg, and Tübingen are scheduled to complete their closure and exit by the end of 2027, while the Singapore production facility is expected to cease operations in the first quarter of 2027.

The company is exploring asset divestiture options for all involved manufacturing sites, including partial transfers or full sales, to mitigate the various impacts resulting from plant closures.

As part of the supporting measures for this restructuring, BioNTech will transfer all COVID-19 vaccine production operations to its long-term partner Pfizer. This adjustment aligns with the industry reality of shrinking vaccine market demand in the post-pandemic era. Workforce optimization and streamlining of the production footprint are core components of the Group’s cost optimization strategy.Target: Achieve approximately €500 million in annual sustainable cost savings by 2029。

This adjustment will enable BioNTech to reallocate financial and human resources, advance the development of its diversified oncology pipeline, with oncology business being the Company’s core strategic growth segment.

BioNTech Chief Financial Officer Ramón Zapata previously stated, “We remain committed to a prudent capital allocation strategy that supports the company’s goal of transforming into a leading biopharmaceutical enterprise with a portfolio of commercialized oncology products by 2030. This production network consolidation is a targeted operational adjustment in response to the post-pandemic market environment, enabling us to concentrate resources on developing novel mRNA immunotherapies for cancer patients.” BioNTech confirmed that during the phased shutdown and transition period across its facilities, there will be no disruption to the supply fulfillment of all existing commercial products or to the production of materials for clinical trials. The company continues to engage in discussions and consultations with local governments, employee representatives, and regional research partners to implement support mechanisms facilitating job transitions for affected employees.

Concurrent with the restructuring announcement, BioNTech unveiled a share repurchase program of up to $1 billion, aimed at optimizing its capital structure and returning excess liquidity to shareholders. In the first quarter of 2026, BioNTech reported total revenue of €118.1 million, a 35% year-on-year decline, primarily driven by persistently weak demand for COVID-19 vaccines; the group posted a net loss of €531.9 million for the period.As of March 31, 2026, BioNTech held a total of €16.7 billion in cash, cash equivalents, and financial securities., thereby providing long-term support for R&D investment and the company’s strategic transformation.

In early July 2026, BioNTech expanded its factory/base streamlining plan, adding JPT Peptides (Berlin site), a wholly-owned peptide R&D and production subsidiary, as the fifth asset slated for divestiture or closure.

JPT Peptides specializes in custom peptide synthesis services required for immunology research and preclinical drug development.BioNTech Plans to Complete the Shutdown or Full Sale of JPT Peptides by End-2026. The Berlin facility has now been incorporated into the group’s global asset integration plan, expanding the number of adjusted sites in Germany to four: Idar-Oberstein, Marburg, Tübingen, and Berlin (JPT Peptides). Coupled with the new production plant in Singapore, the total number of facilities involved in this round of adjustments has increased to five.

The previously announced maximum workforce optimization scale of 1,860 employees, disclosed in May, primarily covered personnel at four mRNA vaccine production bases; the asset divestiture of JPT Peptides resulted inPersonnel changes will be accounted for separately.and incorporate them into the Group’s overall target of achieving €500 million in annual sustainable cost savings by 2029. BioNTech has initiated confidential discussions with potential acquirers regarding all five facilities slated for divestment, with options including either partial asset spin-offs or a complete transfer.

Accompanying the expansion and plant closure plan, management succession arrangements are also being implemented simultaneously.BioNTech Co-Founders Ugur Sahin (who has embarked on a new venture, expected to be an AI+mRNA pharmaceutical company) and Özlem TüreciPlan to step down from current management positions by the end of 2026 and independently conduct early-stage new drug discovery projects outside the group system.

BioNTech has a global workforce of approximately 8,400 employees. The combined headcount reductions from the five sites and personnel optimization measures account for about 22% of its total global workforce, with the vast majority of affected employees based in Germany.

Will it spread to China in the future?Pumice Biologics, remains to be observed. If there is personnel redundancy and overcapacity, it is quite likely.

Attachment, sharing:

Follow the “Yaorongquan” WeChat Official Account to receive updates on new drug information. For learning and sharing purposes only; no investment advice or recommendations are provided!

References:

Yao Rong Quan Data;

FDA/EMA；

NMPA；

https://www.sec.gov/Archives/edgar/data；

https://www.businesswire.com；

https://lifescivoice.com；

https://www.globenewswire.com/n

ews-release；

https://www.businesswire.com/news/home；

Wait.